The appearance and location of this rash are classic signs for necrobiosis lipoidica, a chronic granulomatous skin disease commonly associated with diabetes. The patient’s initial hemoglobin A1c was 12.4%, confirming a diagnosis of type 2 diabetes, and a punch biopsy of the lesion demonstrated a broad zone of necrobiosis in the mid to lower dermis and a chronic inflammatory infiltrate, including plasma cells.

Necrobiosis lipoidica is rare, typically affects middle-aged adults, and is more common in women than in men.¹ Although commonly associated with diabetes (hence the historical name necrobiosis lipoidica diabeticorum), a significant number of cases occur in patients without diabetes.² The pathogenesis is not fully understood. The condition first appears as asymptomatic yellow to red-brown papules and plaques, most commonly on the anterior legs. The lesions then flatten over time, forming broad, yellow-pink patches and plaques.^1,2

Generally, the diagnosis can be made clinically but, if uncertain, a punch biopsy is the preferred technique for confirmation. The differential diagnosis includes chronic cutaneous lupus erythematosus (LE), sarcoidosis, and dermatophytosis. Although the appearance of lesions associated with LE or sarcoidosis can vary, neither one manifests with the yellow coloring seen here. Dermatophytosis typically demonstrates scale and pruritus with an active border; viewing a potassium hydroxide preparation of a skin scraping is usually sufficient to make a diagnosis.

Treatment for necrobiosis lipoidica includes counseling patients to avoid trauma to the affected areas, high-potency topical corticosteroids, and photodynamic therapy.³ Often, lesions are permanent.

For this patient’s diabetes treatment, she was prescribed metformin and insulin glargine and counseled extensively on weight loss, regular exercise, and appropriate diet adjustments. The rash was treated topically with triamcinolone 0.1% cream bid. At her 4-month follow-up, the patient’s hemoglobin A1c value had dropped to 5.4%, and the rash had become less prominent and widespread. The patient was pleased with the cosmetic outcome and declined referral to a dermatologist for further treatment.

‌

Photo and text courtesy of Samuel Dickmann, MD, and James Medley, MD, University of Florida College of Medicine, Gainesville.

The appearance and location of this rash are classic signs for necrobiosis lipoidica, a chronic granulomatous skin disease commonly associated with diabetes. The patient’s initial hemoglobin A1c was 12.4%, confirming a diagnosis of type 2 diabetes, and a punch biopsy of the lesion demonstrated a broad zone of necrobiosis in the mid to lower dermis and a chronic inflammatory infiltrate, including plasma cells.

Necrobiosis lipoidica is rare, typically affects middle-aged adults, and is more common in women than in men.¹ Although commonly associated with diabetes (hence the historical name necrobiosis lipoidica diabeticorum), a significant number of cases occur in patients without diabetes.² The pathogenesis is not fully understood. The condition first appears as asymptomatic yellow to red-brown papules and plaques, most commonly on the anterior legs. The lesions then flatten over time, forming broad, yellow-pink patches and plaques.^1,2

Generally, the diagnosis can be made clinically but, if uncertain, a punch biopsy is the preferred technique for confirmation. The differential diagnosis includes chronic cutaneous lupus erythematosus (LE), sarcoidosis, and dermatophytosis. Although the appearance of lesions associated with LE or sarcoidosis can vary, neither one manifests with the yellow coloring seen here. Dermatophytosis typically demonstrates scale and pruritus with an active border; viewing a potassium hydroxide preparation of a skin scraping is usually sufficient to make a diagnosis.

Treatment for necrobiosis lipoidica includes counseling patients to avoid trauma to the affected areas, high-potency topical corticosteroids, and photodynamic therapy.³ Often, lesions are permanent.

For this patient’s diabetes treatment, she was prescribed metformin and insulin glargine and counseled extensively on weight loss, regular exercise, and appropriate diet adjustments. The rash was treated topically with triamcinolone 0.1% cream bid. At her 4-month follow-up, the patient’s hemoglobin A1c value had dropped to 5.4%, and the rash had become less prominent and widespread. The patient was pleased with the cosmetic outcome and declined referral to a dermatologist for further treatment.

‌

Photo and text courtesy of Samuel Dickmann, MD, and James Medley, MD, University of Florida College of Medicine, Gainesville.

The appearance and location of this rash are classic signs for necrobiosis lipoidica, a chronic granulomatous skin disease commonly associated with diabetes. The patient’s initial hemoglobin A1c was 12.4%, confirming a diagnosis of type 2 diabetes, and a punch biopsy of the lesion demonstrated a broad zone of necrobiosis in the mid to lower dermis and a chronic inflammatory infiltrate, including plasma cells.

Necrobiosis lipoidica is rare, typically affects middle-aged adults, and is more common in women than in men.¹ Although commonly associated with diabetes (hence the historical name necrobiosis lipoidica diabeticorum), a significant number of cases occur in patients without diabetes.² The pathogenesis is not fully understood. The condition first appears as asymptomatic yellow to red-brown papules and plaques, most commonly on the anterior legs. The lesions then flatten over time, forming broad, yellow-pink patches and plaques.^1,2

Generally, the diagnosis can be made clinically but, if uncertain, a punch biopsy is the preferred technique for confirmation. The differential diagnosis includes chronic cutaneous lupus erythematosus (LE), sarcoidosis, and dermatophytosis. Although the appearance of lesions associated with LE or sarcoidosis can vary, neither one manifests with the yellow coloring seen here. Dermatophytosis typically demonstrates scale and pruritus with an active border; viewing a potassium hydroxide preparation of a skin scraping is usually sufficient to make a diagnosis.

Treatment for necrobiosis lipoidica includes counseling patients to avoid trauma to the affected areas, high-potency topical corticosteroids, and photodynamic therapy.³ Often, lesions are permanent.

For this patient’s diabetes treatment, she was prescribed metformin and insulin glargine and counseled extensively on weight loss, regular exercise, and appropriate diet adjustments. The rash was treated topically with triamcinolone 0.1% cream bid. At her 4-month follow-up, the patient’s hemoglobin A1c value had dropped to 5.4%, and the rash had become less prominent and widespread. The patient was pleased with the cosmetic outcome and declined referral to a dermatologist for further treatment.

‌

Photo and text courtesy of Samuel Dickmann, MD, and James Medley, MD, University of Florida College of Medicine, Gainesville.

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.

Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.

Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.

Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.

Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.

Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.

Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.

Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.

Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.

Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.

Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.

Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.

Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.

Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.

Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.

Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.